Presentation is loading. Please wait.

Presentation is loading. Please wait.

Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups. Median (95% CI) exhaled nitric oxide fraction (FeNO)

Published byBrendan Grant Modified over 5 years ago

Similar presentations

Presentation on theme: "Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups. Median (95% CI) exhaled nitric oxide fraction (FeNO)"— Presentation transcript:

1 Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups.
Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups. Analyses of difference between groups at each visit are based on Wilcoxon rank sum tests. p-values at visits 2, 3 and 4 were p=1.00, p=0.01 and p=0.03, respectively. ACQ: Asthma Control Questionnaire. Katrine Feldballe Bernholm et al. ERJ Open Res 2018;4: ©2018 by European Respiratory Society

Download ppt "Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups. Median (95% CI) exhaled nitric oxide fraction (FeNO)"

Similar presentations

A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:

A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:
Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.
Echocardiography view

Echocardiography view
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Survival without tracheostomy

Survival without tracheostomy
Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);
The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.

The correlation between Mycobacterium growth indicator tube (MGIT) time to culture positivity (TTP) and bacterial load count by molecular bacterial load.
Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.
A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.
Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.
Bland–Altman plot of slopes of measurement 1 versus 2

Bland–Altman plot of slopes of measurement 1 versus 2
Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.
Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.
A) Evolution of the yearly mortality rate from year 1 to year 15 of simulation according to the operating rule and to the scenario of organ scarcity. b)

A) Evolution of the yearly mortality rate from year 1 to year 15 of simulation according to the operating rule and to the scenario of organ scarcity. b)
A) Evolution of the proportion of virtual patients (VPs) that died or received a graft while on the high-priority list by year according to the scenario.

A) Evolution of the proportion of virtual patients (VPs) that died or received a graft while on the high-priority list by year according to the scenario.

Similar presentations

Ads by Google